The same guidelines recommend treating T2DM patients with DKD (estimated GFR ≥ 25 mL/min/1.73 m2 and urinary albumin ≥ 300 mg/g creatinine) with canagliflozin, empagliflozin, or dapagliflozin to reduce renal disease progression and CV events. The gene discussed is ALB; the disease is kidney disorder.